Semaglutide is now generic.
Just not in Australia.
But in China, Brazil and Canada, generic drug makers are ready to grab the lucrative market for GLP-1 receptor agonists (RAs), which could drive prices down to $4 for a month of treatment.
Australia must wait longer, but with half a million Australians paying $250 a month for the drugs, the impact is expected to be explosive.
×
Sign in